Regulatory rule preserves LNTH PYLARIFY reimbursement through 2029
Nov 5, 2026, 7:51 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Regulatory clarity reduces earnings and revenue uncertainty for LNTH’s imaging franchise, likely supporting multiple expansion of PYLARIFY adoption and stable pricing. Similar past cases where favorable CMS rulings stabilized reimbursement saw mid-term stock upside.
AI summary
What happened, with direct paths to the underlying reporting
A final rule preserves separate payment for advanced diagnostic imaging agents and confirms PYLARIFY TruVu Transitional Pass-Through status through September 30, 2029, with permanent HCPCS code A9613 now in effect. This reduces reimbursement uncertainty for LNTH’s PSMA PET imaging product, potentially stabilizing demand and supporting longer-term adoption as payer coverage remains clear.
Final rule maintains separate payment for advanced diagnostic imaging agents.
Confirms PYLARIFY TruVu Transitional Pass-Through status through Sept 30, 2029.
Permanent HCPCS code A9613 now in effect.
Reimbursement stability may support LNTH's imaging portfolio adoption and growth.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event